Cutting costs in cultivated meat production relies heavily on rethinking bioreactor designs. Transitioning from pharmaceutical-grade to food-grade systems has reduced expenses by 40–70%, making large-scale production more viable. Companies like BioCraft have demonstrated this shift, slashing costs by 59% in a single redesign. Additionally, using food-grade materials and larger bioreactors - like 42,000-litre or even 260,000-litre systems - has significantly lowered production costs per kilogram.
Key highlights:
- Food-grade bioreactors: Cheaper materials like 304 stainless steel replace costly pharmaceutical-grade components.
- Cost savings in media: Food-grade media is up to 77% cheaper.
- Scaling up: Larger reactors (over 20,000 litres) drastically cut costs, with airlift reactors offering the most savings.
- Current challenges: Smaller companies face high capital costs, and scaling supply chains remains complex.
The industry is pushing towards affordability, but challenges like regulatory clarity and optimising large-scale processes still need addressing.
Cost drivers of cultivated meat production
sbb-itb-c323ed3
Recent Developments Reducing Bioreactor Costs
Cost Comparison: Pharmaceutical-Grade vs Food-Grade Bioreactor Materials for Cultivated Meat
The push to make cultivated meat more affordable continues, with recent advancements driving down costs in materials, production processes, and equipment design.
Lower-Cost Materials: Food-Grade Alternatives Take Centre Stage
A major shift in cultivated meat production is the move from pharmaceutical-grade materials to food-grade alternatives. For example, 316 stainless steel, commonly used in pharmaceutical applications, is being replaced with the more economical 304 stainless steel for bioreactors and related equipment. This switch significantly lowers capital costs while still meeting the functional requirements of food production [2].
Food-grade ingredients also offer remarkable cost savings. On average, food-grade components are 82% cheaper than reagent-grade materials at a 1 kg scale [3]. To illustrate:
- L-Asparagine: £633 per kg (reagent-grade) vs £152 per kg (food-grade)
- L-Glutamine: £344 per kg (reagent-grade) vs £45 per kg (food-grade)
These cost reductions are crucial, especially since growth factors and recombinant proteins often make up more than 90% of total production expenses [4].
Ongoing research is exploring whether animal cells can thrive in food-grade media as effectively as in pharmaceutical-grade conditions. Early findings are encouraging, showing that substituting pharmaceutical-grade components with food-grade alternatives can cut basal media costs by around 77%. For instance, Believer Meats has developed a serum-free medium costing as little as £0.63 per litre [3]. These savings are pivotal for scaling up production.
Scaling Up: Pilot and Industrial Bioreactors
The industry is preparing for a significant leap in production capacity. By 2026, many facilities aim to operate bioreactors in the 10,000- to 50,000-litre range [2]. This marks a shift from small-scale pilot production to industrial-scale operations.
One optimised system has already demonstrated how efficiency improvements can drastically reduce costs - from £437,000 per kg to just £1.95 per kg. These savings are achieved by enhancing bioreactor efficiency, recovering nutrients, and increasing cell density [1].
Simplified Bioreactor Design for Cultivated Meat
Manufacturers are also rethinking equipment design. Instead of adapting pharmaceutical-grade bioreactors, companies now focus on systems built specifically for producing cultivated meat [2]. This approach eliminates unnecessary pharmaceutical features while retaining essential functionality.
"Adopt food-grade materials or other innovative methods, such as determining the bottlenecks or tradeoffs that exist for using more affordable 304 stainless steel alloys compared to 316 alloys for bioreactors and other equipment, to lower equipment expenses, moving away from reliance on pharmaceutical-grade standards." - Good Food Institute [2]
Another trend is the development of species-specific bioreactors. Since fish cells and mammalian cells have different nutrient and environmental needs, companies are designing equipment tailored to each cell type. This targeted approach avoids unnecessary features, making the production process more cost-effective [2][3].
Bioreactor Size and Operation Trends
Common Bioreactor Sizes and Types
In the cultivated meat sector, stirred tank bioreactors (STRs) have become the go-to choice for industrial-scale production. Current techno-economic studies suggest that reactors with capacities exceeding 20,000 litres are now the standard [5].
However, to bring costs down to competitive levels, the push is towards even larger systems. Research from the University of California, Davis highlights the relationship between reactor size and production costs. For instance, using 42,000-litre STRs, cultivated meat can be produced at $30.4 per kg (approximately £23.50 per kg). But scaling up to 210,000-litre STRs cuts costs to $20.8 per kg (around £16.10 per kg), a notable 31.5% reduction [6].
Meanwhile, airlift reactors (ALRs) are gaining attention as a more cost-efficient option for large-scale production. A 260,000-litre ALR can bring costs down to $13.0 per kg (around £10.05 per kg), making it about 37.5% cheaper than the largest STRs [6]. The cost advantage of ALRs lies in their lower operating expenses at higher volumes, making them highly appealing for facilities aiming to produce millions of kilograms annually.
These advancements in reactor sizes are paving the way for further innovations in operational techniques that enhance production efficiency.
Yield Efficiency and Operation Methods
The efficiency of cultivated meat production depends heavily on the operational methods employed. With larger reactors now standard, the focus has shifted to optimising these systems to maximise yield. Current yields vary widely, from 5 to 360 grammes per litre [5], reflecting differences in cell performance and process efficiency. Among the various approaches, fed-batch systems have emerged as the most widely used.
Despite these advancements, the industry faces a significant challenge: much of the available research is based on small-scale tissue engineering, while economic models are built around large-scale industrial production. As Nature Food noted, "TEAs published to date demonstrate that, under the current technological paradigm, CM is unlikely to be competitive with conventional meat" [5]. Addressing this gap will require the development of suspension-tolerant cell lines tailored for industrial use, alongside "intensified bioprocesses" designed to boost cell density and growth rates in these massive bioreactors.
Remaining Challenges and Market Outlook
Capital Barriers for Smaller Companies
For smaller cultivated meat companies, large-scale bioreactor systems come with steep financial hurdles. Building and running these facilities requires substantial investment, especially since pharmaceutical-grade aseptic conditions are often used. These conditions, while ensuring sterility, significantly drive up costs. A shift to food-grade standards could potentially reduce these expenses, but this depends on clearer regulations and a unified industry approach. As regulatory frameworks evolve, they may help ease these financial pressures, allowing companies to transition from pharmaceutical-grade to more cost-effective food-grade processes. However, for many smaller firms, scaling up from laboratory-level tissue engineering to full industrial production remains a daunting and expensive challenge. This highlights the pressing need for affordable, scalable solutions in the market.
Market Growth and Demand for Affordable Solutions
With these financial challenges in mind, the cultivated meat sector is increasingly focused on reducing production costs. Current economic analyses reveal that cultivated meat is still more expensive to produce than traditional meat [5]. This cost disparity drives the industry's push for innovation and efficiency.
"Scale-up feasibility may hinge on cost-saving areas such as use of plant-based media components, food-grade aseptic conditions and extensive scaling of related supply chains." - Goodwin, C.M., Aimutis, W.R. & Shirwaiker, R.A., Authors, Nature Food [5]
Key advancements needed include the development of serum-free differentiation media and facility designs tailored specifically for food production [5]. Additionally, the industry must focus on building scalable supply chains and creating cell lines that can thrive in suspension systems designed for industrial-scale use. Until these critical elements are aligned, achieving cost competitiveness with traditional meat will remain a significant challenge.
Key Takeaways
Switching from pharmaceutical-grade to food-grade bioreactor systems is one of the most effective ways to cut costs in cultivated meat production. Food-grade conditions significantly lower both capital and operating expenses while maintaining food safety standards.
Scaling up to large bioreactors is another essential step for reducing costs, as it enables economies of scale. However, much of the current research is still focused on small, bench-scale systems, which limits commercial potential. To address this, the industry needs to develop cell lines that can grow in suspension and simplify bioreactor designs to suit high-volume food production rather than pharmaceutical requirements. Refining cell culture techniques is also key to making large-scale production viable.
Beyond reactor design, tackling challenges in media and supply chains is equally important. Cost reductions depend on overcoming hurdles such as creating serum-free differentiation protocols and building scalable supply chains for plant-based media components. Without these advancements, achieving price parity with conventional meat will remain out of reach. As noted in a recent analysis:
"Scale-up feasibility may hinge on cost-saving areas such as use of plant-based media components, food-grade aseptic conditions and extensive scaling of related supply chains." - Goodwin, C.M., Aimutis, W.R. & Shirwaiker, R.A., Authors, Nature Food [5]
For those interested in staying updated on these developments, platforms like Cultivated Meat Shop offer educational content that explains how production innovations are helping cultivated meat move closer to becoming a market reality. With continued reductions in bioreactor costs, the dream of affordable, commercially viable cultivated meat is becoming more achievable.
Ongoing innovation and cost-cutting efforts remain essential to transform cultivated meat from a niche product into a mainstream alternative.
FAQs
Is food-grade equipment safe for cultivated meat production?
Food-grade equipment is a safe choice for producing cultivated meat. It serves as a practical alternative to expensive pharmaceutical-grade systems, enabling scalable and cost-efficient processes. This approach ensures production remains efficient without compromising safety standards.
What prevents companies from using bioreactors over 200,000 litres today?
Companies encounter significant hurdles when working with bioreactors exceeding 200,000 litres. The primary challenges stem from the steep initial investment required and the need to maintain high cell densities. Both factors are crucial for making large-scale production of cultivated meat economically viable.
Will cheaper media work as well for animal cells at scale?
Cheaper media can indeed work well for cultivating animal cells at scale, especially when paired with smart process adjustments. Approaches like using serum-free media and implementing recycling techniques have shown they can cut costs significantly while keeping production efficient. These methods are helping make large-scale cultivated meat production more practical without sacrificing quality.
